More than two years ago, we warned about the dangers of treatment methods that are based on the use of antivirals, but it took a long time for the issue of selective pressure caused by antivirals to be widely discussed in scientific societies. Now the Science report published on June 29, 2022 clearly points to this issue

1. Time reveals the
truth!
Antivirals Vs. LDRT
Low-Dose Radiation Therapy for COVID-19

2. Part 1
Dark Side of
Antivirals

3. SMJ Mortazavi, Ph.D
3
Dec 22, 2021

4. SMJ Mortazavi, Ph.D
4
29 June 2022

5. SMJ Mortazavi, Ph.D
5
29 June 2022
“Taken together, the studies show that
“when you put pressure on the virus it
escapes,” says David Ho, a virologist at
Columbia University”
“That rise creates selective pressure on
the virus, favoring mutations that help it
survive in the presence of the drug. And
because each infected person makes
trillions of copies of SARS-CoV-2, the
virus has plenty of opportunities to test
out different mutations as it replicates”.
https://www.science.org/content/article/bad-news-paxlovid-
coronavirus-can-find-multiple-ways-evade-covid-19-drug

6. SMJ Mortazavi, Ph.D
6
“In less than a month, the report by Ghadimi-Moghadam
et al.4 received attention not only for introducing LDRT as
a treatment method for pneumonia in COVID-19 patients
but also for noting the key disadvantages of other treatment
methods such as using antiviral drugs. Rödel et al.5 in their
paper published recently state SARS-COV-2 is an RNA
virus with an expected moderate to high mutation rate …..6
In addition, as discussed in a recent manuscript,4 any
antiviral drug treatment against SARS-CoV-2 would
probably result in a more intense selective pressure on the
virus. Moreover Dilucca et al.7 in their paper published
recently in the Viruses Journal highlight the importance of
LDRT and address the potential problems associated with
the widespread use of different antiviral drugs as discussed
in a recent paper,4 any antiviral drug against SARS-CoV-2
would exert an intense selective pressure on the virus. This
may result in highly adaptive and treatment-resistant virus
types with enhanced pathogenicity”.
Rebuttal:
SMJ Mortazavi, Ph.D
Point/Counterpoint
Low-dose radiation as a treatment for
COVID-19 pneumonia: A threat or real
opportunity?
Seyed Mohammad Javad Mortazavi
Ph.D.,Amirhosein Kefayat M.D.,Jing Cai
Ph.D.
First published: 03 July 2020
https://doi.org/10.1002/mp.14367
2 years ago (July 2020)

7. SMJ Mortazavi, Ph.D
7
Low-Dose Radiation Therapy for COVID-19
Time reveals the truth!

8. Part 2
Which treatment is
buried, Antivirals or
LDRT?

9. SMJ Mortazavi, Ph.D
9
“It is somehow apparent that
using antiviral drugs and
vaccines for COVID-19
treatment would be more
acceptable for patients in
comparison with ionizing
radiations even in low-dose
form. Therefore, further
achievements in these fields
like approving Remdesivir for
COVID-19 treatment25 may
bury the subject of employing
LDRT for COVID-19
treatment“.
Rebuttal:
Amirhosein Kefayat, M.D
Point/Counterpoint
Low-dose radiation as a treatment for
COVID-19 pneumonia: A threat or real
opportunity?
Seyed Mohammad Javad Mortazavi
Ph.D.,Amirhosein Kefayat M.D.,Jing Cai
Ph.D.
First published: 03 July 2020
https://doi.org/10.1002/mp.14367
2 years ago (July 2020)

10. SMJ Mortazavi, Ph.D
10
“. ……any antiviral drug
against SARS-CoV-2
would exert an intense
selective pressure on the
virus. This may result in
highly adaptive and
treatment-resistant virus
types with enhanced
pathogenicity.”.
Rebuttal:
SMJ Mortazavi, Ph.D
Point/Counterpoint
Low-dose radiation as a treatment for
COVID-19 pneumonia: A threat or real
opportunity?
Seyed Mohammad Javad Mortazavi
Ph.D.,Amirhosein Kefayat M.D.,Jing Cai
Ph.D.
First published: 03 July 2020
https://doi.org/10.1002/mp.14367
2 years ago (July 2020)

11. WHO Guideline
Development
Group advises
against use of
remdesivir for
covid-19.
Rodríguez-Tomàs et al. Antioxidants 2022,
11(6), 1184;
https://doi.org/10.3390/antiox11061184,
Published: 16 June 2022
11
Time reveals the truth!
Now, after 2 years, we know that:
 Several groups, including our
own, have shown that whole-lung
radiation at doses of 0.5–1.5 Gy
can accelerate the recovery in
clinical and radiographic status
without acute toxicity
[12,13,14,15,16,17,18,19,20,21].
".
LDRT for COVID-19

12. June2022 Conclusion
 LDRT was feasible, safe and shows promise in the management
of severe COVID-19 pneumonia including in patients progressing
on conventional systemic treatment. Additional
 phase II trials are warranted to identify patients most likely to
benefit from LDRT.